celldex.com (CLDX) Company Sales Volume
Celldex Therapeutics (CLDX) focuses on mast cell immunotherapy, where the success of the drug Barzolvolimab promises a sharp surge in profits. The company's sales volatility clearly demonstrates its financial dynamics, with the current figure standing at 0.00. While geopolitical tensions are hindering global research, strong clinical data and patent protection create a robust barrier in the premium medical segment.
Analytical breakdowns for Celldex Therapeutics
- price and consensus price forecast:
- market capitalization details:
- issuer book value statistics:
- debt and solvency information:
Debt to Capital Celldex Therapeutics|CLDX - Long-Term Debt to Equity|Short-Term Debt to Equity Celldex Therapeutics Inc|CLDX - Company Debts|Debt to Book Capitalization Ratio Celldex Therapeutics, Inc.|CLDX - Company Long-Term Debts|Company Short-Term Indebtedness Celldex Therapeutics|Immediate Liquidity celldex.com
- business earnings and investment ratios data:
CLDX - Net Income|Net Profit Forecast Celldex Therapeutics|CLDX - Price to Earnings Ratio|Future Price to Earnings Multiple celldex.com|CLDX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Celldex Therapeutics, Inc.|CLDX - Operating profit EBITDA|Earnings per share for the trailing year Celldex Therapeutics|CLDX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months celldex.com|CLDX - Earnings per share growth in current year|Expected earnings per share trend next year Celldex Therapeutics
- company sales and revenue statistics:
Comprehensive company analysis:Celldex Corp
Minimizing fundamental risks requires selecting assets with proven cash generation. This indicator captures the daily cash inflow from product sales, reflecting real market demand without accounting adjustments. For Celldex Therapeutics (CLDX), this is a critical marker of the commercialization of patented antibodies against the backdrop of costly trials. By analyzing the company's sales profile, an investor can assess the business's resilience to capital-intensive research.
Key competitors
Revenue and Sales Volume argenx BVBA|Company Revenue BioNTech SE (BNTX)|Abivax SA - Company Sales Volume|Revenue and Sales Volume ADMA (ADMA Biologics, Inc.)|Protagonist Therapeutics, Inc. (PTGX) - Company Total Revenue|Immunovant Corp - Revenue and Sales Volume|Kiniksa Corp (KNSA) - Company Sales|GRFS: Revenue and Sales Volume|Company Total Revenue adaptivebiotech.com (ADPT)|Company Revenue Aurinia Pharmaceuticals Inc.|Company Revenue BCRX|Company Revenue Vera Pharma (VERA)|Company Revenue DNTH (Dianthus Corp)|Revenue and Sales Volume PHVS (Pharvaris N.V.)|ABCL: Company Sales Volume|Tourmaline Bio - Revenue and Sales Volume|Company Total Revenue Precigen Inc|PHAR (Pharming) - Company Sales|Company Sales Volume NKTR|Company Sales UPB|ZBIO: Company Sales Revenue|Company Sales IMNM (Immunome)|Company Total Sales GOSS|Revenue and Sales Volume KALV (KalVista Pharmaceuticals Inc)|Company Sales Revenue SEPN|Pieris Pharmaceuticals - Revenue and Sales Volume|Company Total Revenue savarapharma.com|Rigel Pharmaceuticals, Inc. (RIGL) - Company Revenue|AnaptysBio Inc - Company Sales Revenue|ATXS (Astria Pharma) - Revenue and Sales Volume|Revenue and Sales Volume enGene Corp|Company Revenue RAPT Therapeutics, Inc. (RAPT)|JBIO: Company Annual Revenue|Revenue and Sales Volume ACRS (Aclaris Therapeutics, Inc.)|Kyverna Therapeutics Inc. (KYTX) - Company Total Revenue|TLSA: Company Sales|CABA - Revenue and Sales Volume|VTYX (Ventyx Biosciences) - Company Sales|THTX: Company Total Sales|AVTX (Avalo Therapeutics) - Revenue and Sales Volume|Eledon Pharmaceuticals Inc. (ELDN) - Company Gross Revenue|Revenue and Sales Volume AGEN|Company Sales Climb Bio, Inc CLYM|Company Revenue Zura Bio Limited ZURA|Company Gross Revenue atyrpharma.com (ATYR)|Adagene Corp - Revenue and Sales Volume|ImageneBio Inc (IMA) - Company Sales|shattucklabs.com (STTK) - Company Revenue|EQ (Equillium) - Company Revenue|CNTB (Connect Biopharma Holdings) - Revenue and Sales Volume|Company Sales Volume IMUX (Immunic Inc)|Company Sales ATRA (Atara Biotherapeutics)|inflarx.de - Company Sales Volume|Company Revenue X4 Pharma XFOR|ACET (Adicet Bio Inc.) - Company Annual Revenue|Celularity Corp - Revenue and Sales Volume|Company Sales Revenue INMB (inmunebio.com)|BRNS: Revenue and Sales Volume|Kezar Life Sciences Inc. (KZR) - Revenue and Sales Volume|Company Revenue SAB Biotherapeutics, Inc|AKTX: Company Sales Revenue|Company Revenue Enlivex Therapeutics (ENLV)|Company Sales q32bio.com QTTB|Revenue and Sales Volume GOVX (GeoVax)|Revenue and Sales Volume Edesa Biotech Inc EDSA|IBIO: Company Sales|Company Sales Revenue CARM (Carisma Therapeutics)|XTLB: Revenue and Sales Volume|BOLT - Company Gross Revenue|Company Revenue HCW Biologics, Inc.|Company Sales Aptevo (APVO)|Company Revenue AIM ImmunoTech (AIM)|Company Sales aditxt.com ADTX|GRI Bio, Inc. - Company Sales|Revenue and Sales Volume xortx.com XRTX|HIND - Company Revenue|REVB (Revelation Biosciences Inc) - Company Sales Volume|INDP: Revenue and Sales Volume|Company Total Revenue BiondVax Pharmaceuticals (SCNI)|CALI (CalciMedica Inc) - Revenue and Sales Volume|Company Sales Affimed Therapeutics (AFMD)|Revenue and Sales Volume ALLK|HOOK - Company Total Revenue|Company Revenue IGM Biosciences IGMS|iTeos Pharma - Company Revenue|OCEA - Company Revenue|TCBP: Company Revenue|THRD: Revenue and Sales Volume
